drugset / Trial / NCT00228566

Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00228566

Phase 3 Completed 247 enrolled Cephalon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess patient reported outcomes with armodafinil treatment in terms of improvement in sleepiness, satisfaction with treatment, impact on ability to engage in life activities (ie, daily or work and family and/or social activities), and effects on fatigue. Clinician ratings on patient response to armodafinil treatment will also be assessed.

Timeline

Start
2005-10
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Armodafinil Small molecule 150 mg
Subject Armodafinil Small molecule 250 mg